[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-364401-105":59,"doc-detail-364401-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","nt5e-cd73-as-a-prognostic-biomarker-and-therapeutic-target-associated-with-immune-infiltration-in-lung-adenocarcinoma","NT5E (CD73) as a Prognostic Biomarker and Therapeutic Target Associated with Immune Infiltration in Lung Adenocarcinoma","","NT5E (CD73) is investigated as a prognostic biomarker and therapeutic target in lung adenocarcinoma (LUAD), addressing the limited evidence on its clinical significance and links to immune infiltration. Comprehensive public-database analyses evaluate NT5E expression and its association with immune cell infiltration using CIBERSORT, ESTIMATE, and xCell. NT5E is markedly elevated in LUAD mRNA and protein levels, correlating with metastasis, pathological stage, and poor outcomes. Immune gene programs implicated by GSEA and marker correlations suggest NT5E may modulate immune infiltration, while drug sensitivity highlights MEK1/2 inhibitors selumetinib and PD318088 as potential NT5E-directed agents.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/nt5e-cd73-as-a-prognostic-biomarker-and-therapeutic-target-associated-with-immune-infiltration-in-lung-adenocarcinoma/364401/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/nt5e-cd73-as-a-prognostic-biomarker-and-therapeutic-target-associated-with-immune-infiltration-in-lung-adenocarcinoma/364401.png","ImageObject",300,407,{"name":92,"@type":93},"Emma Wilson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main objective of the study on NT5E in lung adenocarcinoma?","Question",{"text":113,"@type":114},"To determine whether NT5E (CD73) has prognostic value and can act as a therapeutic target in LUAD, particularly in relation to immune cell infiltration.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was the relationship between NT5E expression and immune infiltration assessed?",{"text":118,"@type":114},"The study used comprehensive analyses across public databases and applied computational algorithms such as CIBERSORT, ESTIMATE, and xCell to correlate NT5E levels with immune infiltration and immune cell markers.",{"name":120,"@type":111,"acceptedAnswer":121},"What do the findings suggest about NT5E and patient prognosis in LUAD?",{"text":122,"@type":114},"NT5E is overexpressed at both mRNA and protein levels in LUAD, and higher expression is linked to metastasis, advanced pathological stage, and poor prognosis. The immune-related correlations suggest NT5E may influence prognosis through effects on immune infiltration.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},364401,1790195407,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},3848291630094,"https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nNT5E (CD73) as a prognostic biomarker and therapeutic target associated with immune infiltration in lung adenocarcinoma  \nLeyan Chen1,2,7, Tuoya Qi3,7, Bishu Zhang4,5,7, Xuelong Wang6􀀍 & Mingfeng Zheng1,2􀀍  \nLung adenocarcinoma (LUAD), the most common type of lung cancer, is a leading cause of cancerrelated mortality. NT5E, an ecto-5’-nucleotidase enzyme, has been implicated in cancer progression, particularly in efferocytosis. Despite its potential involvement, the prognostic significance of NT5E and relationship with immune cell infiltration in LUAD have not been extensively explored. In this study, we performed a comprehensive analysis to elucidate the expression patterns of NT5E and its prognostic implications in LUAD using data from diverse public databases. Multiple computational algorithms, including CIBERSORT, ESTIMATE, and xCell, were employed to assess the correlation between NT5E expression and immune cell infiltration. We found that NT5E was significantly overexpressed at both the mRNA and protein levels in LUAD tissues. Elevated NT5Eexpression was significantly linked to multiple clinicopathological factors, including metastasis and pathological stage, and served as a strong predictor of poor prognosis in LUAD patients. Gene Set Enrichment Analysis (GSEA) indicated that NT5E plays a crucial role in regulating immune responses, as evidenced by differential gene expression associated with NT5E levels. A strong positive correlation was observed between NT5E expression and the presence of immune cells, including dendritic cells, macrophages, and CD4+ T cells, as well as the expression of various immune cell markers, suggesting that NT5E may influence the prognosis of LUAD patients by regulating immune cell infiltration. Additionally, drug sensitivity analysis highlights the potential of selumetinib and PD318088, both MEK1/2 inhibitors, to target NT5E in LUAD treatment, suggesting their use as single agents or in combination with other therapies. Collectively, these findings establish NT5E as a promising prognostic biomarker and therapeutic target in LUAD, particularly in the context of immune cell infiltration.  \nKeywords LUAD, NT5E, Prognosis, Immune cell infiltration, Biomarker, Drug sensitivity  \nLung cancer remains the leading cause of cancer-related deaths, exceeding the combined mortality from colorectal, breast, and prostate cancers each year1. The majority of patients are diagnosed at a late stage, either with locally advanced or metastatic disease2. LUAD, the most prevalent histological subtype, accounts for about 50% of all lung cancer cases. For Stage I or II LUAD, the standard treatment typically includes surgical tumor removal, along with adjuvant therapy. However, as the disease advances to Stage III or IV, the approach shifts to chemotherapy or radiotherapy3. Regrettably, traditional chemotherapy drugs are hampered by common limitations such as non-specific targeting, low bioavailability, and the emergence of drug resistance, which restrict their effectiveness in treating cancer4. Nanomedicine delivery systems, with their unique properties, encapsulate therapeutic agents to prevent degradation, allowing for the precise delivery of anticancer drugs to tumor sites while minimizing damage to surrounding tissues, which makes nanomedicine a promising field to explore in lung cancer therapy5. Molecular targeted therapy has emerged as a vital strategy for LUAD treatment, with key targets including the epidermal growth factor receptor (EGFR), hepatocyte growth factor receptor (c-Met), and anaplastic lymphoma kinase (ALK)6. Tyrosine kinase inhibitors like gefitinib and erlotinib have been developed to target EGFR mutations7. However, acquired drug resistance, often due to epigenetic changes  \n1The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi, China. 2Wuxi Medical Center, Nanjing Medical University, Wuxi, Chin","cbCaiqywqzRw3RZc","https://ap.wps.com/l/cbCaiqywqzRw3RZc","pdf",5397391,"English","# Background\n## Current challenges in LUAD treatment\n## Therapeutic directions and biomarkers\n# NT5E role and immune infiltration analysis\n## NT5E expression patterns in LUAD\n## Correlation with clinical factors and prognosis\n## Immune-related pathway enrichment (GSEA)\n# Therapeutic targeting potential\n## Association with immune cell markers\n## Drug sensitivity and candidate inhibitors\n# Study conclusion","[{\"question\":\"What is the main objective of the study on NT5E in lung adenocarcinoma?\",\"answer\":\"To determine whether NT5E (CD73) has prognostic value and can act as a therapeutic target in LUAD, particularly in relation to immune cell infiltration.\"},{\"question\":\"How was the relationship between NT5E expression and immune infiltration assessed?\",\"answer\":\"The study used comprehensive analyses across public databases and applied computational algorithms such as CIBERSORT, ESTIMATE, and xCell to correlate NT5E levels with immune infiltration and immune cell markers.\"},{\"question\":\"What do the findings suggest about NT5E and patient prognosis in LUAD?\",\"answer\":\"NT5E is overexpressed at both mRNA and protein levels in LUAD, and higher expression is linked to metastasis, advanced pathological stage, and poor prognosis. The immune-related correlations suggest NT5E may influence prognosis through effects on immune infiltration.\"}]","NT5E (CD73) as a Prognostic Biomarker and Therapeutic Target Associated with Immune Infiltration in Lung Adenocarcinoma | PDF",1790157428,48,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bd9b238b3f8bbc8ef6a66d29fae78ced.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/67748eded0b5eb30e344924624c77f2d.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8a32df36e698d2d656445074b3bd8c63.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e5d7fc089408caa9cdab5294d662d55f.webp",980,1287]